Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Spierer, Ronen
    Lavi, Idit
    Bloch, Sivan
    Mazar, Marianna
    Golan, Daniel
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4632 - 4639
  • [32] The Impact of Disease-Modifying Therapies of Multiple Sclerosis on the Effectiveness of the BBIBP-CorV COVID-19 Vaccine
    Ghaffari, Mehran
    Moghadam, Nahid Beladi
    Paybast, Sepideh
    Aghamiri, Seyed Hossein
    Haghighi, Mehrdad
    Javadi, Abdolreza
    Rafatpanah, Houshang
    Le, Saba Sadeghi Rashed
    Nahayati, Mohammad Ali
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2024, 19 (06):
  • [33] COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review
    Sharifian-Dorche, Maryam
    Sahraian, Mohammad Ali
    Fadda, Giulia
    Osherov, Michael
    Sharifian-Dorche, Amirhossein
    Karaminia, Maryam
    Saveriano, Alexander William
    La Piana, Roberta
    Antel, Jack P.
    Giacomini, Paul Steven
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [34] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Ronen Spierer
    Idit Lavi
    Sivan Bloch
    Marianna Mazar
    Daniel Golan
    Journal of Neurology, 2023, 270 : 4632 - 4639
  • [35] Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
    Etemadifar, Masoud
    Nouri, Hosein
    Pitzalis, Maristella
    Idda, Maria Laura
    Salari, Mehri
    Baratian, Mahshid
    Mahdavi, Sepide
    Abhari, Amir Parsa
    Sedaghat, Nahad
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09): : 986 - 994
  • [36] Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
    Cabreira, Veronica
    Abreu, Pedro
    Soares-dos-Reis, Ricardo
    Guimaraes, Joana
    Sa, Maria Jose
    VACCINES, 2021, 9 (07)
  • [37] Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review
    Jamali, Elham
    Shapoori, Shima
    Farrokhi, Majid Reza
    Vakili, Sina
    Rostamzadeh, Davoud
    Iravanpour, Farideh
    Oliaee, Razieh Tavakoli
    Jafarinia, Morteza
    VIRAL IMMUNOLOGY, 2023, 36 (06) : 368 - 377
  • [38] Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
    Moehn, Nora
    Konen, Franz E.
    Pul, Refik
    Kleinschnitz, Christoph
    Pruss, Harald
    Witte, Torsten
    Stangel, Martin
    Skripuletz, Thomas
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 12
  • [39] Disease-modifying therapies
    Dodel, R.
    Jessen, F.
    NERVENHEILKUNDE, 2013, 32 (10) : 755 - 761
  • [40] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
12345